REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
REGENXBIO Inc. (Nasdaq: RGNX) announced it will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11:15 a.m. PT in San Francisco, CA. The presentation will include a live webcast accessible on the company's website, with an archive available for 30 days after the event. REGENXBIO is focused on gene therapy, utilizing its proprietary NAV Technology Platform and aims to progress five AAV Therapeutics into pivotal or commercial stages by 2025.
- Scheduled presentation at a high-profile healthcare conference.
- Live and archived webcast allows for wider investor accessibility.
- Commitment to advancing gene therapy with a concrete '5x'25' strategy.
- None.
ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.
41st Annual J.P. Morgan Healthcare Conference
Date: Tuesday, January 10, 2023
Fireside chat: 11:15 a.m. PT
Location: Westin St. Francis, San Francisco, CA
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-41st-annual-jp-morgan-healthcare-conference-301712108.html
SOURCE REGENXBIO Inc.
FAQ
What is REGENXBIO's presentation date at the J.P. Morgan Healthcare Conference?
What time is REGENXBIO's presentation at the conference?
How can I access REGENXBIO's conference presentation?
What is REGENXBIO's strategy for 2025?
